Principal Financial Group Inc. boosted its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 26.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,536,243 shares of the biotechnology company’s stock after purchasing an additional 530,338 shares during the period. Principal Financial Group Inc. owned about 0.91% of Iovance Biotherapeutics worth $20,341,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. ORG Partners LLC bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at about $32,000. Quadrant Capital Group LLC raised its stake in shares of Iovance Biotherapeutics by 1,227.8% in the fourth quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 4,678 shares during the last quarter. Fidelis Capital Partners LLC bought a new position in shares of Iovance Biotherapeutics in the first quarter worth about $87,000. Calton & Associates Inc. bought a new position in shares of Iovance Biotherapeutics in the fourth quarter worth about $98,000. Finally, Inceptionr LLC bought a new position in shares of Iovance Biotherapeutics in the fourth quarter worth about $108,000. 77.03% of the stock is owned by institutional investors.
Iovance Biotherapeutics Stock Down 6.9 %
Iovance Biotherapeutics stock opened at $10.85 on Wednesday. The stock has a market capitalization of $3.04 billion, a PE ratio of -6.03 and a beta of 0.63. Iovance Biotherapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $18.33. The company has a 50 day moving average of $9.26 and a 200-day moving average of $11.17.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on IOVA. Piper Sandler downgraded shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $19.00 to $10.00 in a research note on Monday, July 29th. StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Monday, August 12th. Finally, JMP Securities lowered their price target on shares of Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating for the company in a research report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Featured Articles
- Five stocks we like better than Iovance Biotherapeutics
- What is the Hang Seng index?
- 3 Small Cap Stocks That Insiders Are Buying
- Dividend Capture Strategy: What You Need to Know
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report).
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.